RxDoctor Payments Data

Dhaval Desai

Interventional Cardiology · Corona, CANPI 1164798153

Payments from drug & device makers

$118,097in general payments, 2019–2025

Across 187 payments — averaging $631.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amryt Pharma Holdings Ltd$67K
  • Boston Scientific$26K
  • Medtronic$19K
  • Edwards Lifesciences$3K
  • Abbott$436
  • AstraZeneca$318
  • plus $2K from 24 others

What the payments were for

  • Consulting fees$67,08657%
  • Grants$43,00036%
  • Travel & lodging$6121%
  • Food & beverage$7,2516%
  • Education$1470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,097 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate27$507
Furosemide15$153

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →